Press Releases

Fourth quarter 2019 revenue of $18.1 million, an increase of 18% compared to the prior year period Fourth quarter 2019 gross margin of 78.3%, an increase of 410 basis points from the prior year period Fourth quarter 2019 net loss of $1.6 million, as compared to a pro forma (see tables below) net

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the Cowen and Company 40 th Annual Health

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2019 financial results before the open of the

OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announces two ground-breaking publications in Clinical Infectious Diseases (CID) on the performance of T-SPOT.

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the “Company”), a global, high-growth diagnostics company, today announced they are planning a new initiative to commemorate the coming World Tuberculosis Day, bring the

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the 38th Annual J.P.

OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, is scheduled to participate in the following investor

Third quarter revenue of $21.2 million, an increase of 32% compared to prior year period Gross margin of 73%, an increase of 150 basis points from the prior year period Positive net income of $0.7 million compared to a net loss of ($3.5) million in prior year period OXFORD, United Kingdom and

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release third quarter 2019 financial results before the open of the market on

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), or the Company, a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial